Câncer de testículo

Stephenson A, Bass EB, Bixler BR, et al. Diagnosis and treatment of early-stage testicular cancer: AUA guideline amendment 2023. J Urol. 2024 Jan;211(1):20-5.Texto completo  Resumo

European Association of Urology. Testicular cancer. 2024 [internet publication].Texto completo

Oldenburg J, Berney DM, Bokemeyer C, et al. Testicular seminoma and non-seminoma: ESMO-EURACAN clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022 Apr;33(4):362-75.Texto completo  Resumo

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: testicular cancer [internet publication].Texto completo

American College of Radiology. ACR appropriateness criteria: staging and surveillance of testicular cancer. 2021 [internet publication].Texto completo

Gillessen S, Sauvé N, Collette L, et al. Predicting outcomes in men with metastatic nonseminomatous germ cell tumors (NSGCT): results from the IGCCCG update consortium. J Clin Oncol. 2021 May 10;39(14):1563-74.Texto completo  Resumo

1. Smith ZL, Werntz RP, Eggener SE. Testicular cancer: epidemiology, diagnosis, and management. Med Clin North Am. 2018 Mar;102(2):251-64. Resumo

2. Stephenson A, Bass EB, Bixler BR, et al. Diagnosis and treatment of early-stage testicular cancer: AUA guideline amendment 2023. J Urol. 2024 Jan;211(1):20-5.Texto completo  Resumo

3. World Health Organization. WHO classification of tumours. Urinary and male genital tumours. 5th ed. vol 8. Lyon, France: IARC Press; 2022.

4. Moch H, Cubilla AL, Humphrey PA, et al. The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours. Eur Urol. 2016 Jul;70(1):93-105. Resumo

5. Moch H, Amin MB, Berney DM, et al. The 2022 World Health Organization classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours. Eur Urol. 2022 Nov;82(5):458-68.Texto completo  Resumo

6. Amin MB, Edge S, Green F, et al. AJCC cancer staging manual. 8th ed. (2017). Cham, Switzerland: Springer International; 2017.

7. Brierley JD, Gospodarowicz MK, Wittekind C, eds. Union for International Cancer Control (UICC). TNM classification of malignant tumors. 8th ed. Chichester: Wiley-Blackwell; 2017.

8. Shah YB, Goldberg H, Hu B, et al. Metastatic testicular cancer patterns and predictors: a contemporary population-based SEER analysis. Urology. 2023 Oct;180:182-9.Texto completo  Resumo

9. Oosting SF, de Haas EC, Links TP, et al. Prevalence of paraneoplastic hyperthyroidism in patients with metastatic non-seminomatous germ-cell tumors. Ann Oncol. 2010 Jan;21(1):104-8. Resumo

10. Daniels IR, Layer GT. Testicular tumours presenting as gynaecomastia. Eur J Surg Oncol. 2003 Jun;29(5):437-9. Resumo

11. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249.Texto completo  Resumo

12. Znaor A, Skakkebaek NE, Rajpert-De Meyts E, et al. Global patterns in testicular cancer incidence and mortality in 2020. Int J Cancer. 2022 Sep 1;151(5):692-8. Resumo

13. National Cancer Institute. Cancer stat facts: testicular cancer. 2024 [internet publication].Texto completo

14. Schaffar R, Pant S, Bouchardy C, et al. Testicular cancer in Geneva, Switzerland, 1970-2012: incidence trends, survival and risk of second cancer. BMC Urol. 2019 Jul 10;19(1):64.Texto completo  Resumo

15. Cancer Research UK. Testicular cancer statistics [internet publication].Texto completo

16. Gurney JK, Florio AA, Znaor A, et al. International trends in the incidence of testicular cancer: lessons from 35 years and 41 countries. Eur Urol. 2019 Nov;76(5):615-23. Resumo

17. Huang J, Chan SC, Tin MS, et al. Worldwide distribution, risk factors, and temporal trends of testicular cancer incidence and mortality: a global analysis. Eur Urol Oncol. 2022 Oct;5(5):566-76. Resumo

18. DeSantis CE, Miller KD, Goding Sauer A, et al. Cancer statistics for African Americans, 2019. CA Cancer J Clin. 2019 May;69(3):211-33.Texto completo  Resumo

19. Chovanec M, Cheng L. Advances in diagnosis and treatment of testicular cancer. BMJ. 2022 Nov 28;379:e070499.Texto completo  Resumo

20. Berney DM, Cree I, Rao V, et al. An introduction to the WHO 5th edition 2022 classification of testicular tumours. Histopathology. 2022 Oct;81(4):459-66.Texto completo  Resumo

21. Wang Z, McGlynn KA, Rajpert-De Meyts E, et al. Meta-analysis of five genome-wide association studies identifies multiple new loci associated with testicular germ cell tumor. Nat Genet. 2017 Jul;49(7):1141-7.Texto completo  Resumo

22. Singla N, Lafin JT, Ghandour RA, et al. Genetics of testicular germ cell tumors. Curr Opin Urol. 2019 Jul;29(4):344-9. Resumo

23. Cheng L, Albers P, Berney DM, et al. Testicular cancer. Nat Rev Dis Primers. 2018 Oct 5;4(1):29. Resumo

24. Fukawa T, Kanayama HO. Current knowledge of risk factors for testicular germ cell tumors. Int J Urol. 2018 Apr;25(4):337-44.Texto completo  Resumo

25. Friberg S, Mattson S. On the growth rates of human malignant tumors: implications for medical decision making. J Surg Oncol. 1997;65:284-297. Resumo

26. Tyldesley S, Voduc D, McKenzie M, et al. Surveillance of stage I testicular seminoma: British Columbia Cancer Agency Experience 1992 to 2002. Urology. 2006;67:594-598. Resumo

27. Ronnen EA, Kondagunta GV, Bacik J, et al. Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapy. J Clin Oncol. 2005;23:6999-7004. Resumo

28. Ferguson L, Agoulnik AI. Testicular cancer and cryptorchidism. Front Endocrinol (Lausanne). 2013;4:32.Texto completo  Resumo

29. Yazici S, Del Biondo D, Napodano G, et al. Risk factors for testicular cancer: environment, genes and infections-is it all? Medicina (Kaunas). 2023 Apr 7;59(4):724.Texto completo  Resumo

30. Reuter VE. Origins and molecular biology of testicular germ cell tumors. Mod Pathol. 2005 Feb;18 Suppl 2:S51-60. Resumo

31. Loveday C, Law P, Litchfield K, et al. Large-scale analysis demonstrates familial testicular cancer to have polygenic aetiology. Eur Urol. 2018 Sep;74(3):248-52.Texto completo  Resumo

32. Richiardi L, Akre O, Montgomery SM, et al. Fecundity and twinning rates as measures of fertility before diagnosis of germ-cell testicular cancer. J Natl Cancer Inst. 2004 Jan 21;96(2):145-7.Texto completo  Resumo

33. Dong C, Lonnstedt I, Hemminki K Familial testicular cancer and second primary cancers in testicular cancer patients by histological type. Eur J Cancer. 2001 Oct;37(15):1878-85. Resumo

34. Dieckmann KP, Pichlmeier U. The prevalence of familial testicular cancer: an analysis of two patient populations and a review of the literature. Cancer. 1997 Nov 15;80(10):1954-60. Resumo

35. Zequi Sde C, da Costa WH, Santana TB, et al. Bilateral testicular germ cell tumours: a systematic review. BJU Int. 2012 Oct;110(8):1102-9. Resumo

36. Ilic D, Misso ML. Screening for testicular cancer. Cochrane Database Syst Rev. 2011 Feb 16;(2):CD007853. Resumo

37. Strohsnitter WC, Noller KL, Hoover RN, et al. Cancer risk in men exposed in utero to diethylstilbestrol. J Natl Cancer Inst. 2001 Apr 4;93(7):545-51.Texto completo  Resumo

38. Powles T, Bower M, Daugaard G, et al. Multicenter study of human immunodeficiency virus-related germ cell tumors. J Clin Oncol. 2003 May 15;21(10):1922-7. Resumo

39. Kulacoglu H, Köckerling F. Hernia and cancer: the points where the roads intersect. Front Surg. 2019;6:19.Texto completo  Resumo

40. Pettersson A, Richiardi L, Nordenskjold A, et al. Age at surgery for undescended testis and risk of testicular cancer. N Engl J Med. 2007 May 3;356(18):1835-41.Texto completo  Resumo

41. Ye H, Ulbright TM. Difficult differential diagnoses in testicular pathology. Arch Pathol Lab Med. 2012 Apr;136(4):435-46. Resumo

42. Dogra V, Bhatt S. Acute painful scrotum. Radiol Clin North Am. 2004 Mar;42(2):349-63. Resumo

43. Marcell AV, Bell DL, Joffe A; Society for Adolescent Health and Medicine, SAHM Male Health Special Interest Group. The male genital examination: a position paper of the Society for Adolescent Health and Medicine. J Adolesc Health. 2012 Apr;50(4):424-5. Resumo

44. Richie JP. Neoplasms of the testis. In: Walsh PC, Retik AB, Vaughan ED, et al., eds. Campell's urology. 7th ed. Philadelphia, PA: WB Saunders Company; 2001:2417-8.

45. American College of Radiology. ACR appropriateness criteria: newly diagnosed palpable scrotal abnormality. 2021 [internet publication].Texto completo

46. European Association of Urology. Testicular cancer. 2024 [internet publication].Texto completo

47. Oldenburg J, Berney DM, Bokemeyer C, et al. Testicular seminoma and non-seminoma: ESMO-EURACAN clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022 Apr;33(4):362-75.Texto completo  Resumo

48. Sohaib SA, Cook G, Koh DM. Imaging studies for germ cell tumors. Hematol Oncol Clin North Am. 2011 Jun;25(3):487-502, vii. Resumo

49. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: testicular cancer [internet publication].Texto completo

50. Pfail J, Santiago I, Jang TL, et al. Contralateral testicular biopsy in men with testicular cancer. Eur Urol Focus. 2024 May;10(3):370-2.Texto completo  Resumo

51. 't Hoen LA, Bhatt NR, Radmayr C, et al. The prognostic value of testicular microlithiasis as an incidental finding for the risk of testicular malignancy in children and the adult population: a systematic review. On behalf of the EAU pediatric urology guidelines panel. J Pediatr Urol. 2021 Dec;17(6):815-31.Texto completo  Resumo

52. American College of Radiology. ACR appropriateness criteria: staging and surveillance of testicular cancer. 2021 [internet publication].Texto completo

53. Sturgeon CM, Duffy MJ, Stenman UH, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem. 2008 Dec;54(12):e11-79.Texto completo  Resumo

54. Milose JC, Filson CP, Weizer AZ, et al. Role of biochemical markers in testicular cancer: diagnosis, staging, and surveillance. Open Access J Urol. 2011 Dec 30;4:1-8.Texto completo  Resumo

55. Dieckmann KP, Radtke A, Geczi L, et al. Serum levels of microRNA-371a-3p (M371 Test) as a new biomarker of testicular germ cell tumors: results of a prospective multicentric study. J Clin Oncol. 2019 Jun 1;37(16):1412-23.Texto completo  Resumo

56. Nestler T, Schoch J, Belge G, et al. MicroRNA-371a-3p-the novel serum biomarker in testicular germ cell tumors. Cancers (Basel). 2023 Aug 3;15(15):3944.Texto completo  Resumo

57. Che M, Tamboli P, Ro JY, et al. Bilateral testicular germ cell tumors: twenty-year experience at M. D. Anderson Cancer Center. Cancer. 2002 Sep 15;95(6):1228-33. Resumo

58. Street E, Joyce A, Wilson J. BASHH UK guideline for the management of epididymo-orchitis, 2010. Int J STD AIDS. 2011 Jul;22(7):361-5.Texto completo  Resumo

59. Hassan MA. Presentation and management outcome of symptomatic epididymal cysts in children: a case series. Int J Surg Open. 2023;55:100626.Texto completo

60. Kingston M, French, Higgins S, et al. UK national guidelines on the management of syphilis 2015. Int J STD AIDS. 2016 May;27(6):421-46.Texto completo  Resumo

61. International Germ Cell Cancer Collaborative Group. International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol. 1997 Feb;15(2):594-603.Texto completo  Resumo

62. Gillessen S, Sauvé N, Collette L, et al. Predicting outcomes in men with metastatic nonseminomatous germ cell tumors (NSGCT): results from the IGCCCG update consortium. J Clin Oncol. 2021 May 10;39(14):1563-74.Texto completo  Resumo

63. Beyer J, Collette L, Sauvé N, et al. Survival and new prognosticators in metastatic seminoma: results from the IGCCCG-update consortium. J Clin Oncol. 2021 May 10;39(14):1553-62.Texto completo  Resumo

64. US Preventive Services Task Force. Screening for testicular cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med. 2011 Apr 5;154(7):483-6.Texto completo  Resumo

65. Ruf CG, Schmidt S, Kliesch S, et al. Testicular germ cell tumours' clinical stage I: comparison of surveillance with adjuvant treatment strategies regarding recurrence rates and overall survival-a systematic review. World J Urol. 2022 Dec;40(12):2889-2900.Texto completo  Resumo

66. Kondagunta GV, Bacik J, Bajorin D, et al. Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors. J Clin Oncol. 2005 Dec 20;23(36):9290-4. Resumo

67. Mead GM, Fossa SD, Oliver RT, et al. Randomized trials in 2466 patients with stage I seminoma: patterns of relapse and follow-up. J Natl Cancer Inst. 2011 Feb 2;103(3):241-9.Texto completo  Resumo

68. Fosså SD, Chen J, Schonfeld SJ, et al. Risk of contralateral testicular cancer: a population-based study of 29,515 U.S. men. J Natl Cancer Inst. 2005 Jul 20;97(14):1056-66.Texto completo  Resumo

69. Aydin AM, Zemp L, Cheriyan SK, et al. Contemporary management of early stage testicular seminoma. Transl Androl Urol. 2020 Jan;9(suppl 1):S36-44.Texto completo  Resumo

70. Heinzelbecker J, Schmidt S, Lackner J, et al. Therapy of clinical stage IIA and IIB seminoma: a systematic review. World J Urol. 2021 Nov 15 [Epub ahead of print].Texto completo  Resumo

71. Chung P, Mayhew LA, Warde P, et al. Management of stage I seminomatous testicular cancer: a systematic review. Clin Oncol (R Coll Radiol). 2010 Feb;22(1):6-16. Resumo

72. Warde PR, Chung P, Sturgeon J, et al. Should surveillance be considered the standard of care in stage I seminoma? J Clin Oncol (Meeting Abstracts). 2005;23(suppl 16):abstr 4520.

73. Cohn-Cedermark G, Stahl O, Tandstad T, et al. Surveillance vs. adjuvant therapy of clinical stage I testicular tumors - a review and the SWENOTECA experience. Andrology. 2015 Jan;3(1):102-10.Texto completo  Resumo

74. Tyrrell HEJ, Church DN, Joseph J, et al. Changing practice evaluation-stage 1 seminoma: outcomes with adjuvant treatment versus surveillance: risk factors for recurrence and optimizing follow-up protocols-experience from a supraregional center. Clin Genitourin Cancer. 2018 Jun;16(3):240-4. Resumo

75. Petrelli F, Coinu A, Cabiddu M, et al. Surveillance or adjuvant treatment with chemotherapy or radiotherapy in stage I seminoma: a systematic review and meta-analysis of 13 studies. Clin Genitourin Cancer. 2015 Oct;13(5):428-34. Resumo

76. Patel HD, Srivastava A, Alam R, et al. Radiotherapy for stage I and II testicular seminomas: Secondary malignancies and survival. Urol Oncol. 2017 Oct;35(10):606.e1-7. Resumo

77. Fossa SD, Horwich A, Russell JM, et al. Optimal planning target volume for stage I testicular seminoma. J Clin Oncol. 1999 Apr;17(4):1146. Resumo

78. Chung P, Warde P. Testicular cancer: germ cell tumours. BMJ Clin Evid. 2016 Jan 7;2016. pii: 1807.Texto completo  Resumo

79. Hamilton RJ, Canil C, Shrem NS, et al. Canadian Urological Association consensus guideline: Management of testicular germ cell cancer. Can Urol Assoc J. 2022 Jun;16(6):155-73.Texto completo  Resumo

80. Heidenreich A, Paffenholz P, Hartmann F, et al. Retroperitoneal lymph node dissection in clinical stage IIA/B metastatic seminoma: results of the COlogne Trial of Retroperitoneal Lymphadenectomy In Metastatic Seminoma (COTRIMS). Eur Urol Oncol. 2024 Feb;7(1):122-7. Resumo

81. Daneshmand S, Cary C, Masterson T, et al. Surgery in early metastatic seminoma: a phase II trial of retroperitoneal lymph node dissection for testicular seminoma with limited retroperitoneal lymphadenopathy. J Clin Oncol. 2023 Jun 1;41(16):3009-18.Texto completo  Resumo

82. Papachristofilou A, Bedke J, Hayoz S, et al. Single-dose carboplatin followed by involved-node radiotherapy for stage IIA and stage IIB seminoma (SAKK 01/10): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022 Nov;23(11):1441-50. Resumo

83. Daugaard G, Gundgaard MG, Mortensen MS, et al. Surveillance for stage I nonseminoma testicular cancer: outcomes and long-term follow-up in a population-based cohort. J Clin Oncol. 2014 Dec 1;32(34):3817-23. Resumo

84. Daugaard G, Petersen PM, Rorth M. Surveillance in stage I testicular cancer. APMIS. 2003 Jan;111(1):76-83. Resumo

85. Brewster SF. Challenging the EAU 2009 guidelines on testis cancer: the risk-adapted management of stage I nonseminomatous germ cell tumours: surveillance yields equal results with less toxicity. Euro Urol. 2010 Apr;9(3):459-61.Texto completo

86. Stephenson AJ, Sheinfeld J. Management of patients with low-stage nonseminomatous germ cell testicular cancer. Curr Treat Options Oncol. 2005 Sep;6(5):367-77. Resumo

87. Cullen M, Huddart R, Joffe J, et al. The 111 study: a single-arm, phase 3 trial evaluating one cycle of bleomycin, etoposide, and cisplatin as adjuvant chemotherapy in high-risk, stage 1 nonseminomatous or combined germ cell tumours of the testis. Eur Urol. 2020 Mar;77(3):344-51.Texto completo  Resumo

88. Calabrò F, Albers P, Bokemeyer C, et al. The contemporary role of chemotherapy for advanced testis cancer: a systematic review of the literature. Eur Urol. 2012 Jun;61(6):1212-21. Resumo

89. Nichols CR, Catalano PJ, Crawford ED, et al. Randomized comparison of cisplatin and etoposide with either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors. J Clin Oncol. 1998 Apr;16(4):1287-93. Resumo

90. Feldman DR, Bosl GJ, Sheinfeld J, et al. Medical treatment of advanced testicular cancer. JAMA. 2008 Feb 13;299(6):672-84.Texto completo  Resumo

91. Bokemeyer C, Schmoll HJ, Ludwig E, et al. The anti-tumour activity of ifosfamide on heterotransplanted testicular cancer cell lines remains unaltered by the uroprotector mesna. Br J Cancer. 1994 May;69(5):863-7.Texto completo  Resumo

92. Daneshmand S, Albers P, Fosså SD, et al. Contemporary management of postchemotherapy testis cancer. Eur Urol. 2012 Nov;62(5):867-76. Resumo

93. Treglia G, Sadeghi R, Annunziata S, et al. Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography in the postchemotherapy management of patients with seminoma: systematic review and meta-analysis. Biomed Res Int. 2014;2014:852681.Texto completo  Resumo

94. Kondagunta GV, Bacik J, Donadio A, et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol. 2005 Sep 20;23(27):6549-55.Texto completo  Resumo

95. Loehrer PJ Sr, Lauer R, Roth BJ, et al. Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Intern Med. 1988 Oct 1;109(7):540-6. Resumo

96. Loehrer PJ Sr, Gonin R, Nichols CR, et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol. 1998 Jul;16(7):2500-4. Resumo

97. Bhatia S, Abonour R, Porcu P, et al. High-dose chemotherapy as initial salvage in patients with relapsed testicular cancer. J Clin Oncol. 2000 Oct 1;18(19):3346-51. Resumo

98. Lorch A, Kleinhans A, Kramar A, et al. Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: long-term results of a prospective randomized trial. J Clin Oncol. 2012 Mar 10;30(8):800-5. Resumo

99. Feldman DR, Sheinfeld J, Bajorin DF, et al. TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. J Clin Oncol. 2010 Apr 1;28(10):1706-13.Texto completo  Resumo

100. Einhorn LH, Williams SD, Chamness A, et al. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med. 2007 Jul 26;357(4):340-8.Texto completo  Resumo

101. McHugh DJ, Feldman DR. Conventional-dose versus high-dose chemotherapy for relapsed germ cell tumors. Adv Urol. 2018;2018:7272541.Texto completo  Resumo

102. Incrocci L, Hop WC, Wijnmaalen A, et al. Treatment outcome, body image and sexual functioning after orchiectomy and radiotherapy for stage I-II testicular seminoma. Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1165-73. Resumo

103. Hermans BP, Sweeney CJ, Foster RS, et al. Risk of systemic metastases in clinical stage I nonseminoma germ cell testis tumor managed by retroperitoneal lymph node dissection. J Urol. 2000 Jun;163(6):1721-4. Resumo

104. Mazumdar M, Bajorin DF, Bacik J, et al. Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy. J Clin Oncol. 2001 May 1;19(9):2534-41. Resumo

105. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Cancer. 2003 Jun 15;97(12):3090-8. Resumo

106. Abouassaly R, Fossa SD, Giwercman A, et al. Sequelae of treatment in long-term survivors of testis cancer. Eur Urol. 2011 Sep;60(3):516-26. Resumo

107. Oktay K, Harvey BE, Partridge AH, et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018 Jul 1;36(19):1994-2001.Texto completo  Resumo

108. Lauritsen J, Hansen MK, Bandak M, et al. Cardiovascular Risk Factors and Disease After Male Germ Cell Cancer. J Clin Oncol. 2020 Feb 20;38(6):584-592.Texto completo  Resumo

109. Lubberts S, Groot HJ, de Wit R, et al. Cardiovascular disease in testicular cancer survivors: identification of risk factors and impact on quality of life. J Clin Oncol. 2023 Jul 1;41(19):3512-22.Texto completo  Resumo

110. Shrem NS, Wood L, Hamilton RJ, et al. Testicular cancer survivorship: long-term toxicity and management. Can Urol Assoc J. 2022 Aug;16(8):257-72. Resumo

111. Groot HJ, Lubberts S, de Wit R, et al. Risk of solid cancer after treatment of testicular germ cell cancer in the platinum era. J Clin Oncol. 2018 Aug 20;36(24):2504-13.Texto completo  Resumo

112. Milano MT, Dinh PC, Yang H, et al. Solid and hematologic neoplasms after testicular cancer: a US population-based study of 24 900 survivors. JNCI Cancer Spectr. 2020 Jun;4(3):pkaa017.Texto completo  Resumo

113. Kaufmann E, Antonelli L, Albers P, et al. Oncological follow-up strategies for testicular germ cell tumours: a narrative review. Eur Urol Open Sci. 2022 Oct;44:142-9.Texto completo  Resumo